202 related articles for article (PubMed ID: 2588960)
1. Plasma levels of von Willebrand factor and plasminogen activator in patients with arterial thromboembolism--with special reference to their correlation to the increased catabolism of both fibrinogen and platelets.
Matsumoto M; Uchiyama T; Kobayashi N; Maekawa T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1105-14. PubMed ID: 2588960
[TBL] [Abstract][Full Text] [Related]
2. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
3. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
Wieczorek I; Ludlam CA; MacGregor IR
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
[TBL] [Abstract][Full Text] [Related]
4. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age.
Aillaud MF; Pignol F; Alessi MC; Harle JR; Escande M; Mongin M; Juhan-Vague I
Thromb Haemost; 1986 Jun; 55(3):330-2. PubMed ID: 3092390
[TBL] [Abstract][Full Text] [Related]
5. Altered endothelial function following the Fontan procedure.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
[TBL] [Abstract][Full Text] [Related]
6. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].
Rość D; Drewniak W; Kinasz-Rózycka I; Kulwas A; Michalski A
Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251
[TBL] [Abstract][Full Text] [Related]
7. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
9. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis and spinal injury. Relationship to post-traumatic deep vein thrombosis.
Petäjä J; Myllynen P; Rokkanen P; Nokelainen M
Acta Chir Scand; 1989; 155(4-5):241-6. PubMed ID: 2508383
[TBL] [Abstract][Full Text] [Related]
12. Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm.
Jern C; Selin L; Tengborn L; Jern S
Thromb Haemost; 1997 Aug; 78(2):887-91. PubMed ID: 9268190
[TBL] [Abstract][Full Text] [Related]
13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
14. [Platelet activation and endothelial factors in standard exercise test before and after menopause].
Krzysiek J; Milewicz T; Dybkowski R; Janczak-Saif A; Dembińska-Kieć A; Anna AZ; Guevara I; Sztefko K; Radowicki S; Dubiel JS; Klimek R
Przegl Lek; 2001; 58(5):419-25. PubMed ID: 11603175
[TBL] [Abstract][Full Text] [Related]
15. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
17. [Impaired fibrinolytic response to the venous occlusion test in patients with cryptogenic colitis].
Gris JC; Schved JF; Raffanel C; Dubois A; Ribard D; Balmes JL
Gastroenterol Clin Biol; 1991; 15(12):933-8. PubMed ID: 1783249
[TBL] [Abstract][Full Text] [Related]
18. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
19. Defective interaction between von Willebrand factor and platelet glycoprotein Ib--a familial study of peripheral arterial occlusive disease.
Kauhanen P; Beer JH; Lassila R
Thromb Haemost; 1997 May; 77(5):849-55. PubMed ID: 9184391
[TBL] [Abstract][Full Text] [Related]
20. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease.
de Romeuf C; Mazurier C
Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
